Clinical Trial Update: Study of PEG-rIL-29 (or PEG-IFN Lambda) in Subjects With Chronic Hepatitis C Virus Infection [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating PEG-rIL-29 (PEG-IFN lambda) in adults with chronic hepatitis C virus infection has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• PEG-rIL-29 (PEG-IFN Lambda) (pegylated interferon lambda (IFN-λ1))

Snippet

Sponsor: ZymoGenetics | Conditions: Hepatitis C, Chronic | Phase 1 | Status: COMPLETED